Aging in fragile X syndrome

Journal of Neurodevelopmental Disorders

Volumn 2, Issue 2, 2010, Pages 70-76

  Utari, Agustini ^a,b   Adams, Evan ^a   Berry Kravis, Elizabeth ^c   Chavez, Alyssa ^a,d   Scaggs, Felicia ^c   Ngotran, Lily ^a   Boyd, Antoniya ^a   Hessl, David ^a,d   Gane, Louise W ^a   Tassone, Flora ^e   Tartaglia, Nicole ^f   Leehey, Maureen A ^g   Hagerman, Randi J ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DIPONEGORO UNIVERSITY   (Indonesia)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Children's Hospital Colorado   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Fragile X syndrome; Medical problems; Movement disorder

Indexed keywords

EID: 77954954470     PISSN: 18661947     EISSN: 18661955     Source Type: Journal    
DOI: 10.1007/s11689-010-9047-2     Document Type: Article

References (45)

1. Allen EG, He W, Yadav-Shah M, Sherman SL. A study of the distributional characteristics of FMR1 transcript levels in 238 individuals. Hum Genet. 2004; 114: 439-47.
2. Berry-Kravis E. Epilepsy in fragile X syndrome. Dev Med Child Neurol. 2002; 44: 724-8.
3. Berry-Kravis E, Abrams L, Coffey SM, Hall DA, Greco C, Gane LW, et al. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord. 2007; 22: 2018-30.
4. Caligiuri MP, Teulings HL, Dean CE, Niculescu AB, Lohr J. Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone. Hum Mov Sci. 2009; 28: 633-42.
5. Chonchaiya W, Schneider A, Hagerman RJ. Fragile X: a family of disorders. Adv Pediatr. 2009; 56: 165-86.
6. Coffey SM, Cook K, Tartaglia N, Tassone F, Nguyen DV, Pan R, et al. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A. 2008; 146A: 1009-16.
7. Cortese L, Caligiuri MP, Williams R, Schieldrop P, Manchanda R, Malla A, et al. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol. 2008; 28: 69-73.
8. Crawford DC, Meadows KL, Newman JL, Taft LF, Scott E, Leslie M, et al. Prevalence of the fragile X syndrome in African-Americans. Am J Med Genet. 2002; 110: 226-33.
9. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 2008; 52: 818-27.
10. de Rijk MC, Breteller MM, Graveland GA, Ott A, Grobbee DE, van der Meche FG, et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology. 1995; 45(12): 2143-6.
11. Desai HB, Donat J, Shokeir MH, Munoz DG. Amyotrophic lateral sclerosis in a patient with fragile X syndrome. Neurology. 1990; 40: 378-80.
12. Fernandez-Carvajal I, Walichiewicz P, Xiaosen X, Pan R, Hagerman PJ, Tassone F. Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn. 2009; 11: 324-9.
13. Greco C, Jin L-W, Tassone F, Hagerman P, Hagerman R. Neuropathological analysis of four fragile X syndrome (FXS) autopsy brains. 14th International Workshop on Fragile X Syndrome and X-linked mental retardation, Bahia, Brazil, 2009.
14. Hagerman RJ. Physical and behavioral phenotype. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: Diagnosis, treatment and research. 3rd ed. Baltimore: The Johns Hopkins University Press; 2002. p. 3-109.
15. Hagerman P, Stafstorm C. Origins of epilepsy in fragile X syndrome. Epilepsy Currents. 2009; 9: 108-12.
16. Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology. 2001; 57: 127-30.
17. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, et al. Advances in the treatment of fragile X syndrome. Pediatrics. 2009; 123: 378-90.
18. Harris SW, Hessl D, Goodlin-Jones B, Ferranti J, Bacalman S, Barbato I, et al. Autism profiles of males with fragile X syndrome. Am J Ment Retard. 2008; 113: 427-38.
19. Hatton DD, Sideris J, Skinner M, Mankowski J, Bailey Jr DB, Roberts J, et al. Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am J Med Genet A. 2006; 140A: 1804-13.
20. Hessl D, Tassone F, Cordeiro L, Koldewyn K, McCormick C, Green C, et al. Brief report: aggression and stereotypic behavior in males with fragile X syndrome-moderating secondary genes in a "single gene" disorder. J Autism Dev Disord. 2008; 38: 184-9.
21. Hoeffer C, Klann E, Wong H, Hagerman R, Tassone F. Dysfunction of protein synthesis mediated by mTOR-dependent signaling in fragile x syndrome. 14th International Workshop on Fragile X Syndrome and X-linked mental retardation, Bahia, Brazil, 2009.
22. Jin P, Warren ST. Understanding the molecular basis of fragile X syndrome. Hum Mol Genet. 2000; 9: 901-8.
23. Khan LK, Sobush K, Keener D, Goodman K, Lowry A, Kakietek J, et al. Recommended community strategies and measurements to prevent obesity in the United States. MMWR Recomm Rep. 2009; 58: 1-26.
24. Lachiewicz AM, Gullion CM, Spiridigliozzi GA, Aylsworth AS. Declining IQs of young males with the fragile X syndrome. Am J Ment Retard. 1987; 92: 272-8.
25. Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev. 2004; 10: 31-41.
26. Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, et al. mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res. 2009; 69: 7160-4.
27. Miller LJ, McIntosh DN, McGrath J, Shyu V, Lampe M, Taylor AK, et al. Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: a preliminary report. Am J Med Genet. 1999; 83: 268-79.
28. Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005; 80: 33-43.
29. Muslimovic D, Post B, Speelman JD, De Haan RJ, Schmand B. Cognitive decline in Parkinson's disease: a prospective longitudinal study. J Int Neuropsychol Soc. 2009; 15: 426-37.
30. Nolin SL, Glicksman A, Houck Jr GE, Brown WT, Dobkin CS. Mosaicism in fragile X affected males. Am J Med Genet. 1994; 51: 509-12.
31. Nowicki ST, Tassone F, Ono MY, Ferranti J, Croquette MF, Goodlin-Jones B, et al. The Prader-Willi phenotype of fragile X syndrome. J Dev Behav Pediatr. 2007; 28: 133-8.
32. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006; 295: 1549-55.
33. Oostra BA, Willemsen R. FMR1: a gene with three faces. Biochim Biophys Acta. 2009; 1790: 467-77.
34. Orti-Pareja M, Jimenez-Jimenez FJ, Vazquez A, Catalan MJ, Zurdo M, Burguera JA, et al. Drug-induced tardive syndromes. Parkinsonism Relat Disord. 1999; 5: 59-65.
35. Riddle JE, Cheema A, Sobesky WE, Gardner SC, Taylor AK, Pennington BF, et al. Phenotypic involvement in females with the FMR1 gene mutation. Am J Ment Retard. 1998; 102: 590-601.
36. Sabaratnam M. Pathological and neuropathological findings in two males with fragile-X syndrome. J Intellect Disabil Res. 2000; 44(Pt 1): 81-5.
37. Schultz-Pedersen S, Hasle H, Olsen JH, Friedrich U. Evidence of decreased risk of cancer in individuals with fragile X. Am J Med Genet. 2001; 103: 226-30.
38. Sund R, Pukkala E, Patja K. Cancer incidence among persons with fragile X syndrome in Finland: a population-based study. J Intellect Disabil Res. 2009; 53: 85-90.
39. Tassone F, Hagerman RJ, Loesch DZ, Lachiewicz A, Taylor AK, Hagerman PJ. Fragile X males with unmethylated, full mutation trinucleotide repeat expansions have elevated levels of FMR1 messenger RNA. Am J Med Genet. 2000; 94: 232-6.
40. Tassone F, Hagerman RJ, Taylor AK, Hagerman PJ. A majority of fragile X males with methylated, full mutation alleles have significant levels of FMR1 messenger RNA. J Med Genet. 2001; 38: 453-6.
41. Waldstein G, Hagerman R. Aortic Hypoplasia and Cardiac Valvular Abnormalities in a Boy with Fragile-X Syndrome. Am J Med Genet. 1988; 30: 83-98.
42. Waldstein G, Mireau G, Ahmad R, Thibadee U, Haserman BJ, Caldwell S. Fragile X syndrome: skin elastin abnormalities. In: Gildert E, Opitz J, editors. Genetic aspect of developmental pathology. New York: Alan R. Liss Inc.; 1986. p. 103-14.
43. Wang H, Wu LJ, Kim SS, Lee FJ, Gong B, Toyoda H, et al. FMRP acts as a key messenger for dopamine modulation in the forebrain. Neuron. 2008; 59: 634-47.
44. Westmark CJ, Malter JS. FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol. 2007; 5: e52.
45. Wright-Talamante C, Cheema A, Riddle JE, Luckey DW, Taylor AK, Hagerman RJ. A controlled study of longitudinal IQ changes in females and males with fragile X syndrome. Am J Med Genet. 1996; 64: 350-5.